Skip to main content
Press release February 25, 2026

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Terns Pharmaceuticals, Inc. (TERN)

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care Conference Format: Fireside Chat Date and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside Chat Date and Time: Monday, March 9, 2026 at 1:40 p.m. ET Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Format: 1x1 Meetings Date: Tuesday, March 10, 2026 Location: Miami, FL The Citizens Life Sciences Conference Format: Fireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ET Location: Miami, FL Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations. About Terns Pharmaceuticals Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more information, please visit: www.ternspharma.com. Contacts for Terns Investors Justin Ng [email protected] Media Jenna Urban CG Life [email protected]
View original release